| Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes YK Wang, A Bashashati, MS Anglesio, DR Cochrane, DS Grewal, G Ha, ... Nature genetics 49 (6), 856-865, 2017 | 251 | 2017 |
| Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence H Fleury, N Malaquin, V Tu, S Gilbert, A Martinez, MA Olivier, A Sauriol, ... Nature communications 10 (1), 2556, 2019 | 173 | 2019 |
| Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease H Fleury, L Communal, E Carmona, L Portelance, SL Arcand, K Rahimi, ... Genes & cancer 6 (9-10), 378, 2015 | 54 | 2015 |
| Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines H Fleury, E Carmona, VG Morin, L Meunier, JY Masson, PN Tonin, ... Oncotarget 8 (25), 40152, 2017 | 46 | 2017 |
| Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction AM Couturier, H Fleury, AM Patenaude, VL Bentley, A Rodrigue, ... Nucleic acids research, gkw921, 2016 | 46 | 2016 |
| Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors M Marques, MC Beauchamp, H Fleury, I Laskov, S Qiang, M Pelmus, ... BMC medicine 13, 1-8, 2015 | 30 | 2015 |
| Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models MN Brodeur, K Simeone, K Leclerc-Deslauniers, H Fleury, E Carmona, ... Scientific reports 11 (1), 18183, 2021 | 27 | 2021 |
| Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems B Patra, MA Lateef, MN Brodeur, H Fleury, E Carmona, B Peant, ... PLoS One 15 (12), e0244549, 2020 | 19 | 2020 |
| Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor α in breast cancer cells L Edjekouane, S Benhadjeba, M Jangal, H Fleury, N Gévry, E Carmona, ... Oncotarget 7 (47), 77276, 2016 | 17 | 2016 |
| A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene CT Fierheller, L Guitton-Sert, WM Alenezi, T Revil, KK Oros, Y Gao, ... Genome medicine 13 (1), 1-26, 2021 | 14 | 2021 |
| The APE2 nuclease is essential for DNA double-strand break repair by microhomology-mediated end joining H Fleury, MK MacEachern, CM Stiefel, R Anand, C Sempeck, ... Molecular Cell 83 (9), 1429-1445. e8, 2023 | 9 | 2023 |
| Pre-activation of autophagy impacts response to olaparib in prostate cancer cells M Cahuzac, P Langlois, B Péant, H Fleury, AM Mes-Masson, F Saad Communications biology 5 (1), 251, 2022 | 9 | 2022 |
| Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution A St-Georges-Robillard, M Cahuzac, B Péant, H Fleury, MA Lateef, ... Integrative Biology 11 (4), 130-141, 2019 | 9 | 2019 |
| NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer Z Boudhraa, K Zaoui, H Fleury, M Cahuzac, S Gilbert, G Tchakarska, ... Oncogene 41 (3), 309-320, 2022 | 5 | 2022 |
| The CD73 immune checkpoint promotes tumor cell metabolic fitness D Allard, I Cousineau, EH Ma, B Allard, Y Bareche, H Fleury, J Stagg eLife 12, e84508, 2023 | 2 | 2023 |
| Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability S Gilbert, B Péant, N Malaquin, V Tu, H Fleury, K Leclerc-Desaulniers, ... Molecular Cancer Therapeutics 21 (3), 407-418, 2022 | 2 | 2022 |
| The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene CT Fierheller, L Guitton-Sert, WM Alenezi, T Revil, KK Oros, K Bedard, ... medRxiv, 2020.05. 04.20090407, 2020 | 2 | 2020 |
| 53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer M Skulimowski, J Bourbonnais, N Malaquin, H Fleury, I Clement, ... bioRxiv, 2023.09. 30.560286, 2023 | | 2023 |
| Abstract| PDF| Full Text| Supplementary Materials| Order a Reprint| https://doi. org/10.18632/genesandcancer. 76 H Fleury, L Communal, E Carmona, L Portelance, SL Arcand, K Rahimi, ... | | |
